Aptose Biosciences Inc. Files 8-K on Shareholder Vote Matters

TL;DR

APTO filed an 8-K for shareholder vote matters. Expect corporate action.

AI Summary

Aptose Biosciences Inc. filed an 8-K on January 28, 2025, reporting on matters submitted to a vote of its security holders as of January 27, 2025. The company, previously known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.

Why It Matters

This filing indicates that Aptose Biosciences Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can signal significant corporate changes or strategic shifts that may carry inherent risks.

Key Numbers

• 001-32001 — Commission File Number (Identifies the company's SEC filing history)
• 98-1136802 — I.R.S. Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Aptose Biosciences Inc. (company) — Registrant
• Lorus Therapeutics Inc. (company) — Former company name
• Imutec Pharma Inc. (company) — Former company name
• January 27, 2025 (date) — Date of earliest event reported
• January 28, 2025 (date) — Date of report

FAQ

Filing Documents

• d883134d8k.htm (8-K) — 28KB
• 0001193125-25-014413.txt ( ) — 154KB
• apto-20250127.xsd (EX-101.SCH) — 3KB
• apto-20250127_lab.xml (EX-101.LAB) — 19KB
• apto-20250127_pre.xml (EX-101.PRE) — 12KB
• d883134d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 APTOSE BIOSCIENCES INC. (Exact name of registrant as specified in its charter) Canada 001-32001 98-1136802 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 66 Wellington Street West , Suite 5300 TD Bank Tower, Box 48 Toronto , Ontario M5K 1E6 Canada (Address of Principal Executive Offices) (Zip Code) (647) 479-9828 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value APTO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.07. Submission of Matters to a Vote of Security Holders. On January 27, 2025, Aptose Biosciences Inc., or the "Corporation," held a Special Meeting of the shareholders of the Corporation (the "Meeting"). At the Meeting, shareholders voted in favor of all items of business, as indicated below: Proposal No. 1-Reverse Stock Split The shareholders approved an amendment to the Corporation's Articles of Incorporation, as amended, to, at the discretion of the board of directors (the "Board"), effect a reverse stock split at a ratio between 10-to-1 and 30-to-1, with the ratio within such range to be determined at the discretion of the Board, based on the votes listed below: Votes For % Votes For Votes Against % Votes Against Abstain Broker Non- Votes 17,427,255 81.25% 3,965,788 18.49% 55,115 2 Proposal No. 2-Meeting Adjournment The Corporation's shareholders voted to approve a resolution permitting the adjournment of the meeting, if necessary or appropriate, to solicit additional proxies in the event there are not sufficient votes to approve Proposal No. 1. Votes For % Votes For Votes Against % Votes Against Abstain Broker Non- Votes 16,397,171 76.45% 4,874,696 22.73% 176,292 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 28, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR